Free Trial

Theravance Biopharma (TBPH) Earnings Date, Estimates & Call Transcripts

Theravance Biopharma logo
$9.91 -0.06 (-0.60%)
(As of 11:01 AM ET)

Theravance Biopharma Latest Earnings Summary

Upcoming Q4
Earnings Date
Feb. 24Estimated
Actual EPS
(Nov. 12)
-$0.26 Missed By -$0.16
Consensus EPS
(Nov. 12)
-$0.10

Theravance Biopharma announced Q3 2024 earnings on November 12, 2024, reporting an EPS of -$0.26, which missed the consensus estimate of -$0.10 by $0.16. Quarterly revenue was reported to be $16.87 million, above analysts' expectations of $16.11 million. With a trailing EPS of -$1.01, Theravance Biopharma's earnings are expected to grow next year, from ($1.06) to $0.25 per share.

TBPH Upcoming Earnings

Theravance Biopharma's next earnings date is estimated for Monday, February 24, 2025, based off prior year's reporting schedules.

Get Theravance Biopharma Earnings Alerts

Want to stay updated on the latest earnings announcements and upcoming reports? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Theravance Biopharma and other key companies, straight to your inbox.

Sign Up
Skip Charts & View Estimated and Actual Earnings Data

TBPH Earnings Estimates and Actuals by Quarter

The chart below shows up to four years of a company's earnings history. The dark blue line represents the company's actual earnings per share. The light blue area represents the range of Wall Street analysts' earnings estimates for each quarter.

TBPH Estimated and Actual Revenue by Quarter

The chart below shows up to four years of a company's revenue history. The dark blue line represents the company's actual revenue. The light blue line represents the company's estimated revenue based on the consensus of Wall Street analysts for each quarter.

Theravance Biopharma Analyst EPS Estimates

QuarterNumber of EstimatesLow EstimateHigh EstimateAverage Estimate
Q1 20242-$0.40-$0.37-$0.39
Q2 20241-$0.28-$0.28-$0.28
Q3 20242-$0.23-$0.17-$0.20
Q4 20242-$0.16-$0.10-$0.13
FY 20247-$1.07-$0.92-$1.00
Q1 20251-$0.25-$0.25-$0.25
Q2 20251-$0.24-$0.24-$0.24
Q3 20251-$0.03-$0.03-$0.03
Q4 20251$0.51$0.51$0.51
FY 20254-$0.01-$0.01-$0.01
Q1 20261-$0.07-$0.07-$0.07
Q2 20261-$0.04-$0.04-$0.04

Theravance Biopharma Earnings History by Quarter

DateQuarterConsensus EstimateReported EPSBeat/MissGAAP EPSRevenue EstimateActual RevenueLinks
2/24/2025
(Estimated)
------- 
11/12/2024Q3 2024-$0.1030-$0.26 -$0.1570-$0.26$16.11M$16.87M        
8/5/2024Q2 2024-$0.09-$0.34 -$0.25-$0.34$15.81M$14.26M        
5/13/2024Q1 2024-$0.28-$0.24+$0.04-$0.24$14.54M$14.50M  
2/26/2024Q4 2023-$0.15-$0.17 -$0.02-$0.17$17.49M$17.57M
11/7/2023Q3 2023-$0.21-$0.17+$0.04-$0.17$15.59M$15.69M
8/7/2023Q2 2023-$0.22-$0.28 -$0.06-$0.28$15.24M$13.75M
5/8/2023Q1 2023-$0.27-$0.32 -$0.05-$0.29$13.82M$10.42M
2/27/2023Q4 2022-$0.20-$0.21 -$0.01-$0.27$18.25M$14.65M

Theravance Biopharma Earnings - Frequently Asked Questions

Theravance Biopharma has not confirmed its next earnings publication date, but the company's estimated earnings date is Monday, February 24th, 2025 based off last year's report dates. Learn more on TBPH's earnings history.

In the previous quarter, Theravance Biopharma (NASDAQ:TBPH) missed the analysts' consensus estimate of ($0.10) by $0.16 with a reported earnings per share (EPS) of ($0.26). Learn more on analysts' earnings estimate vs. TBPH's actual earnings.

The conference call for Theravance Biopharma's latest earnings report can be listened to online.
Listen to Conference Call

The conference call transcript for Theravance Biopharma's latest earnings report can be read online.
Read Transcript

Theravance Biopharma (NASDAQ:TBPH) has a recorded annual revenue of $57.42 million.

Theravance Biopharma (NASDAQ:TBPH) has a recorded net income of -$55.19 million. TBPH has generated -$1.01 earnings per share over the last four quarters.

Theravance Biopharma's earnings are expected to grow from ($1.06) per share to $0.25 per share in the next year.

`

More Earnings Resources from MarketBeat



This page (NASDAQ:TBPH) was last updated on 11/21/2024 by MarketBeat.com Staff
From Our Partners